Skip Navigation


Age and Ageing Advance Access originally published online on November 22, 2005
Age and Ageing 2006 35(1):85-86; doi:10.1093/ageing/afi212
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/1/85    most recent
afi212v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Murphy, C.
Right arrow Articles by Cullen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, C.
Right arrow Articles by Cullen, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Intravenous immunoglobulin for resistant Clostridium difficile infection

C. Murphy, M. Vernon and M. Cullen

Department of Geriatric Medicine, Wythenshawe Hospital, Manchester, UK

Address Correspondence to: C. Murphy. Email: drclmurphy{at}aol.com

Clostridium difficile (CD)-associated diarrhoea and colitis may relapse in up to 20% of treated patients. We present a patient who failed to respond over a 6-month period to treatment either singly or in combination with metronidazole, vancomycin, rifampicin, cholestyramine and probiotics. Her diarrhoea rapidly resolved after a 3-day course of intravenous immunoglobulin. This treatment may compensate for a failed immune response to CD toxin and should be considered for relapsing CD-associated diarrhoea where there is no response to conventional treatment strategies.

Keywords: Clostridium difficile, diarrhoea, immunoglobulin, elderly

Received February 16, 2005; accepted in revised form August 24, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
T. Z Jodlowski, R. Oehler, L. W Kam, and I. Melnychuk
Emerging Therapies in the Treatment of Clostridium difficile-Associated Disease
Ann. Pharmacother., December 1, 2006; 40(12): 2164 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. Surowiec, A. G Kuyumjian, M. A Wynd, and C. E Cicogna
Past, Present, and Future Therapies for Clostridium difficile-Associated Disease
Ann. Pharmacother., December 1, 2006; 40(12): 2155 - 2163.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.